

ESM Table 5. Change from baseline to week 52 in vital signs, lipid parameters, and calcitonin (safety population)

	Placebo (n = 101)	Albiglutide 30 mg weekly (n = 101)	Albiglutide 50 mg weekly (n = 99)
Systolic (mm Hg)	1.3 (13.09)	-2.8 (12.14)	-1.3 (13.37)
Diastolic (mm Hg)	0.1 (9.17)	-0.8 (8.21)	-0.8 (8.95)
Heart rate (bpm)	0.8 (8.92)	2.5 (8.44)	0.8 (9.00)
Total cholesterol (mmol/L)	-0.057 (1.0454)	-0.312 (0.8948)	-0.101 (0.6237)
LDL (mmol/L)	-0.141 (0.6927)	-0.278 (0.6999)	-0.130 (0.5928)
HDL (mmol/L)	0.079 (0.1508)	0.051 (0.1975)	0.042 (0.2250)
Free fatty acid (mmol/L)	-0.003 (0.2186)	-0.038 (0.2170)	-0.007 (0.2099)
Triglycerides (mmol/L)	0.037 (1.9900)	-0.379 (2.5157)	0.014 (0.8548)
Calcitonin (pmol/L)	-0.038 (0.479)	0.043 (0.113)	0.097 (0.237)

Data are mean (SD).